Grafa News and Videos — Page 47

Monash IVF Group (ASX:MVF) reported FY26 revenue of $269.5 million alongside an underlying net profit after tax of $16.1 million.

Austal (ASX:ASB) moved to a net loss after tax of $53.6 million, down from an $89.7 million net profit in FY25.

The A2 Milk Company (ASX:A2M) revealed that members of its executive team sold portions of their equity holdings.

Liontown (ASX:LTR) achieved a maiden net profit after tax of $93 million for the financial year ended June 30.

The Australian Taxation Office identified approximately 6000 investment property sales between July 1, 2020, and June 30, 2025.

Australia is evaluating new requirements for Meta (NASDAQ:META) and other social media giants to make recommendation algorithms opt-in to limit harmful content.

• SpaceX announced plans to launch Nvidia-powered AI satellite systems in Q4 2027, advancing its previous target for initial orbital data center deployments.
• The project combines SpaceX launch infrastructure with Nvidia Vera Rubin computing systems designed for AI workloads in orbit.
• The broader AI infrastructure market is expanding as semiconductor firms, cloud providers, and data center operators invest in higher computing capacity.

• DICK’S Sporting Goods (NYSE:DKS) reported Q2 2026 sales of $5.59 billion, up 53.2% year over year, after incorporating the Foot Locker acquisition into results.
• The company’s operating margin declined to 7.9% from 12.4%, while GAAP EPS fell to $3.50 as Foot Locker reported weaker performance and pressured profitability.
• The broader athletic retail sector faces pressure from changing footwear demand, inventory levels, and companies’ strategies to adjust product mixes and margins. 

Better Home & Finance Holding Company (NASDAQ:BETR) urged shareholders to reject former CEO Vishal Garg’s consent solicitation campaign, which seeks to remove five board members and install replacement directors.

Amarin (NASDAQ:AMRN) reported new post hoc REDUCE-IT Legacy analysis data showing that patients with high adherence to icosapent ethyl experienced an approximately 29%–30% relative reduction in the primary cardiovascular endpoint compared with placebo.